Citations

Clear

9383 citation(s) found for "Thomas, PS".

Toward the Future: A Race‐Agnostic, Bayesian Approach to Defining Glomerular Filtration for Personalized Drug Dosing
Scheetz, Marc H. , Lodise, Thomas P. , Rhodes, Nathaniel J. , Pai, Manjunath P. , Frazee, Erin N. , Neely, Michael , Frazee, Erin N , Neely, Michael N , Scheetz, Marc H , Rhodes, Nathaniel J , Lodise, Thomas P.

Mayo Clinic

Clinical Pharmacology & Therapeutics | June 11, 2026 | Volume: 120 | Issue: 3 | Pages: 639-647

10.1002/cpt.70358 | PMID 42274272 Get It

Accurate assessment of renal function is fundamental to dosing renally eliminated drugs. For decades, serum creatinine–based estimating equations have been used to approximate glomerular filtration rate (GFR) for this purpose. While these equations perform reasonably well at the population level, they exhibit substantial individual‐level imprecision and inaccuracy. Simultaneously, recent efforts to remove race from estimating equations addressed important ethical concerns but did not resolve the core limitation of population‐based estimation for individual drug dosing. In this perspective, we argue that personalized dosing requires a shift away from demographic surrogates toward direct measurement of renal clearance and clarify when incremental therapeutic complexity is warranted. We review the limitations of endogenous biomarkers, discuss the role of cystatin C, and propose exogenously measured GFR using iohexol integrated within a Bayesian pharmacometric framework as a clinically actionable approach to individualized drug dosing. Practically, this framework can be implemented by administering a small iohexol dose, collecting sparse timed samples, estimating absolute mGFR and its uncertainty with Bayesian software, and using that posterior estimate to refine renal dose selection.
Changes in Pitching Performance After Ulnar Collateral Ligament Reconstruction Differ Among Major League Baseball Starting and Relief Pitchers
Almonroeder, Thomas, Knapp, Zachary, Dunavan, Charles, Krebs, Jay, Jones, Margaret T. , Fields, Jennifer B. , Bittner, Michael H., Merfeld, Brandon, Fields, Jennifer B , Almonroeder, Thomas Gus , Merfeld, Brandon , Jagim, Andrew R.

Mayo Clinic

Applied Sciences | June 11, 2026 | Volume: 16 | Issue: 12 | Pages: 5846

10.3390/app16125846 Get It

The primary aim of this study was to examine pitching performance metrics before and after ulnar collateral ligament reconstruction (UCLR) among Major League Baseball (MLB) starting and relief pitchers. The following information was extracted from the “Tommy John Surgery List” database regarding UCLR surgeries among MLB pitchers: UCLR date, pitcher type (starting pitcher, relief pitcher), and age at time of UCLR. Pitching performance metrics were extracted from the Baseball Savant online platform for the two seasons immediately prior to UCLR (pre) and the two seasons immediately following returning to pitching after UCLR (post). Fifty-nine pitchers were included in this study (29 starting pitchers, 30 relief pitchers). The outcome measures included the number of pitches thrown, earned run average (ERA), walks plus hits per inning pitched (WHIP), strikeout percentage, whiff percentage, walk percentage, batting average against, ground ball percentage, and fastball velocity. There was a pitcher type-by-time interaction effect for ERA (p = 0.01; η2 = 0.12) and WHIP (p = 0.01; η2 = 0.12). Starting pitcher ERA increased from 3.68 to 4.40 from pre- to post-surgery, while relief pitcher ERA decreased from 4.47 to 3.90. In addition, starting pitcher WHIP increased from 1.22 to 1.29 from pre- to post-surgery, while relief pitcher WHIP decreased from 1.38 to 1.28. There was a main effect of time for pitches thrown (p = 0.04; η2 = 0.07). Significant differences between starting and relief pitchers were observed for changes in ERA and WHIP following UCLR, whereas no pitcher type-by-time interactions were observed for the remaining performance metrics. Both starting and relief pitchers threw fewer pitches following UCLR, while fastball velocity and other key pitching performance metrics remained largely unchanged.
Miv-cel CD19 CAR T-Cell Therapy Shows Efficacy and Safety in Stiff Person Syndrome in a Pivotal, Multicenter, Phase 2 Study (KYSA-8) (LS2.008)
Ζεκερίδου, Αναστασία , Gutman, Jonathan, Lowe, Mallory, Eggmann, Sadie, McKeon, Andrew, Pittock, Sean J., Yi, Jessica J., Newsome, Scott D., Chou, Justin, Blarcom, Tom Van, Han, Xue, Sun, John, Sengupta, Shouvonik , Tooker, Ryan, Mehta, Aditi, Grayson, Dena , Gehchan, N., Piquet, Amanda L. , Gergis, Usama , Gutman, Jonathan A. , Kenderian, Saad S. , McKeon, Andrew , Pittock, Sean J. , Rakočević, Goran , Dalakas, Marinos C.

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000217905 Get It

Autopsy Validation of Biomarker-derived Biological Classifications in Lewy Body Disease (P11-13.011)
Chiu, S. Y., Aden, Abdirahim, Shill, Holly, Driver-Dunckley, Erika, Mehta, SH, Belden, Christine, Serrano, Geidy, Beach, T, Adler, Charles, Choudhury, Parichita , Chiu, Shannon , Tremblay, Cécilia , Shill, Holly A. , Driver‐Dunckley, Erika , Mehta, Shyamal H. , Mastrangelo, Andrea , Parchi, Piero , Belden, Christine M. , Serrano, Geidy E, Beach, Thomas G. , Adler, Charles

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000215727 Get It

Efficacy of Eplontersen According to Baseline Polyneuropathy Severity in Patients with Hereditary Transthyretin Amyloidosis: A Subgroup Analysis of the NEURO-TTRansform Index Study (S32.009)
Brannagan, Thomas, Berk, John, Gertz, MA, Khella, Sami, Masri, Ahmad, Maurer, Mathew, Kwoh, Theodore, Pola, Maksym , Nåtman, Jonatan , Berk, John L. , Gertz, Morie A. , Masri, Ahmad , Maurer, Mathew S , Waddington‐Cruz, Márcia , Obici, Laura

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000215351 Get It